Drug-resistant TB (DR-TB) is on the rise with 558,000 new cases a year. It is the only airborne drug-resistant epidemic and responsible for nearly 1/3 of all deaths from antimicrobial resistance (AMR) globally.
A new report by The Economist Intelligence Unit (EIU), and made possible with support from Johnson & Johnson, emphasizes the urgent need for global action to address the growing threat of DR-TB.